Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Genomic Revolution ETF (ARKG) vs Arm Holdings plc (ARM) Price & Performance

ARK Genomic Revolution ETFTrade
Arm Holdings plcTrade

Price performance (Past 24H)

Key statistics

ARK Genomic Revolution ETF vs Arm Holdings plc — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while Arm Holdings plc trades at $271.14 (market cap $286.06B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.

ARKGARM
Sector
Sector/ThematicTechnology
52-Week High
$44.55$439.46
52-Week Low
$24.02$104.55
Market Cap
$286.06B
Enterprise Value
$282.64B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Genomic Revolution ETF

ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.

The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.

Arm Holdings plc

ARM stock trades at $282.57, down 1.43% over 24 hours, with a bullish technical outlook supported by moving averages and key support at $272. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 beating the $0.40 estimate. Revenue grew to $4.01B in 2025, with a net income margin of 20.25%, though valuation multiples remain elevated with a P/E of 273.32.

The outlook is positive due to AI-driven growth in licensing and royalties, with management targeting $25B revenue by FY31. However, risks include stretched valuation, smartphone market headwinds, and execution challenges. Analyst consensus is bullish with a $329.80 price target, suggesting 17% upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG

About Arm Holdings plc

Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.

Read more on ARM